Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

1. Mateos, M.-V.
2. Bringhen, S.
3. Richardson, P.G.
4. Lahuerta, J.J.
5. Larocca, A.
6. Oriol, A.
7. Boccadoro, M.
8. García-Sanz, R.
9. Raimondo, F.D.
10. Esseltine, D.-L.
11. van de Velde, H.
12. Desai, A.
13. Londhe, A.
14. Miguel, J.F.S.
15. Palumbo, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2013.099341 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus